Oral Fosamprenavir + Sodium Alginate for GERD

Inclusion criteria

• Patient aged 18-65 selected as candidate for anti-reflux surgery by study providers.
• Patient has received, and continued having GERD symptoms during, standard-labeled dose, daily, PPI therapy for a minimum of 8 weeks before the Screening Visit.
• Patient has a diagnosis of GERD with endoscopy and/or pH-metry test within the past two years demonstrating 1 or more of the following:

• Erosive esophagitis (Grade A or greater based on the Los Angeles classification of esophagitis; Appendix 3)
• Evidence of pathological acid reflux (pH < 4 for ≥ 4-6% off therapy or ≥ 1-4% on therapy) during a 24-hour time interval of pH testing
• Patient reports heartburn severity (HS, Item #1 on mRESQ-eD) ≥ 3 (moderate) on at least 2 days and has an average HS of ≥ 2 (mild) during the last 7 days of the Pretreatment Period before Randomization.

Exclusion criteria

• Patient is suspected of having, functional upper gastrointestinal disorders such as functional dyspepsia or functional heartburn diagnosed by the Rome IV criteria; Appendix 4.
• Patient has endoscopically confirmed eosinophilic esophagitis (EE).